How Low Can Gilenia Go? Panel Wants Reduced-Dose Phase IV Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee votes that the agency should approve the first-ever oral MS drug, but should require Novartis to study what it hopes will be a safer version of the product.
You may also be interested in...
Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market
FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.
Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market
FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.
Gilenia Advisory Committee: Is REMS + Phase IV > FDA Safety Concerns?
Novartis' oral multiple sclerosis drug Gilenia (fingolimod) faces an unusually large briefing package from FDA focused on safety concerns.